Author argues SLS is undervalued after the Phase 3 AML immunotherapy update and expects the stock to rise into P3 results.
SLS — LONG The author claims GPS Immunotherapy is working for AML Remission Maintenance based on the Phase 3 trial update. He argues SLS is worth much more than shorts have sold it for and that the price will continue rising until the P3 results are announced, then launch.
Recent Market Activity, Following the Phase 3 Trial Update is telling everyone paying attention GPS Immunotherapy is working for AML Remission Maintenance, and SLS is worth a F ton more than what Shorts Sold this equity for - Price will continue Rising until the P3 results are announced, and then it will absolutely Launch.
This Reddit post, published January 04, 2026, features u/Run4theRoses2 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Run4theRoses2 · Tickers: SLS